{"pmid":32486846,"title":"Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?","text":["Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?","J Diabetes Sci Technol","Koufakis, Theocharis","Metallidis, Symeon","Zebekakis, Pantelis","Ajjan, Ramzi A","Kotsa, Kalliopi","32486846"],"journal":"J Diabetes Sci Technol","authors":["Koufakis, Theocharis","Metallidis, Symeon","Zebekakis, Pantelis","Ajjan, Ramzi A","Kotsa, Kalliopi"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32486846","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1177/1932296820932155","keywords":["covid-19","sglt2 inhibitors","diabetes","diabetic ketoacidosis"],"e_drugs":["Glucose"],"weight":0,"_version_":1668623433673474049,"score":9.490897,"similar":[{"pmid":32433344,"title":"Judicious Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes on Coronavirus-19 Pandemic.","text":["Judicious Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes on Coronavirus-19 Pandemic.","Sodium glucose cotransporter-2 inhibitors (SGLT2i), a novel anti-diabetic drug blocks the reabsorption of glucose in proximal tubules of kidney, are demonstrated to have cardiovascular and renal benefits for people with diabetes. The benefits are associated with the significant increase of intrarenal angiotensin-converting enzyme II (ACE2) expression and blood volume contraction. However, the increased ACE2 may be detrimental to patients infected with the coronavirus infection 2019 (COVID-19), which is found to invades cells via the entry receptor of ACE2. Besides, SGLT2i induced natriuretic effect may also increase the risk of acute kidney injury and affect the hemodynamic stability during systemic infection disease. In the article, we explain the mechanisms why the use of SGLT2i in people with diabetes may lead to worse outcomes and suggest clinician to judiciously use it during COVID-19 pandemic.","J Chin Med Assoc","Chen, Chun-Fan","Chen, Yung-Tai","Chen, Tz-Heng","Chen, Fan-Yu","Yang, Yi-Ping","Wang, Mong-Lien","Huo, The-Ia","Chang, Yuh-Lih","Tan, Ann Charis","Lin, Chih-Ching","32433344"],"abstract":["Sodium glucose cotransporter-2 inhibitors (SGLT2i), a novel anti-diabetic drug blocks the reabsorption of glucose in proximal tubules of kidney, are demonstrated to have cardiovascular and renal benefits for people with diabetes. The benefits are associated with the significant increase of intrarenal angiotensin-converting enzyme II (ACE2) expression and blood volume contraction. However, the increased ACE2 may be detrimental to patients infected with the coronavirus infection 2019 (COVID-19), which is found to invades cells via the entry receptor of ACE2. Besides, SGLT2i induced natriuretic effect may also increase the risk of acute kidney injury and affect the hemodynamic stability during systemic infection disease. In the article, we explain the mechanisms why the use of SGLT2i in people with diabetes may lead to worse outcomes and suggest clinician to judiciously use it during COVID-19 pandemic."],"journal":"J Chin Med Assoc","authors":["Chen, Chun-Fan","Chen, Yung-Tai","Chen, Tz-Heng","Chen, Fan-Yu","Yang, Yi-Ping","Wang, Mong-Lien","Huo, The-Ia","Chang, Yuh-Lih","Tan, Ann Charis","Lin, Chih-Ching"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32433344","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1097/JCMA.0000000000000354","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667342288326492161,"score":103.76146},{"pmid":32456064,"title":"Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis.","text":["Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis.","Patients with diabetes have been reported to have enhanced susceptibility to severe or fatal COVID-19 infections, including a high risk of being admitted to intensive care units with respiratory failure and septic complications. Given the global prevalence of diabetes, affecting over 450 million people worldwide and still on the rise, the emerging COVID-19 crisis poses a serious threat to an extremely large vulnerable population. However, the broad heterogeneity and complexity of this dysmetabolic condition, with reference to etiologic mechanisms, degree of glycemic derangement and comorbid associations, along with the extensive sexual dimorphism in immune responses, can hamper any patient generalization. Even more relevant, and irrespective of glucose-lowering activities, DPP4 inhibitors and GLP1 receptor agonists may have a favorable impact on the modulation of viral entry and overproduction of inflammatory cytokines during COVID-19 infection, although current evidence is limited and not univocal. Conversely, SGLT2 inhibitors may increase the likelihood of COVID-19-related ketoacidosis decompensation among patients with severe insulin deficiency. Mindful of their widespread popularity in the management of diabetes, addressing potential benefits and harms of novel antidiabetic drugs to clinical prognosis at the time of a COVID-19 pandemic deserves careful consideration.","Int J Environ Res Public Health","Mirabelli, Maria","Chiefari, Eusebio","Puccio, Luigi","Foti, Daniela Patrizia","Brunetti, Antonio","32456064"],"abstract":["Patients with diabetes have been reported to have enhanced susceptibility to severe or fatal COVID-19 infections, including a high risk of being admitted to intensive care units with respiratory failure and septic complications. Given the global prevalence of diabetes, affecting over 450 million people worldwide and still on the rise, the emerging COVID-19 crisis poses a serious threat to an extremely large vulnerable population. However, the broad heterogeneity and complexity of this dysmetabolic condition, with reference to etiologic mechanisms, degree of glycemic derangement and comorbid associations, along with the extensive sexual dimorphism in immune responses, can hamper any patient generalization. Even more relevant, and irrespective of glucose-lowering activities, DPP4 inhibitors and GLP1 receptor agonists may have a favorable impact on the modulation of viral entry and overproduction of inflammatory cytokines during COVID-19 infection, although current evidence is limited and not univocal. Conversely, SGLT2 inhibitors may increase the likelihood of COVID-19-related ketoacidosis decompensation among patients with severe insulin deficiency. Mindful of their widespread popularity in the management of diabetes, addressing potential benefits and harms of novel antidiabetic drugs to clinical prognosis at the time of a COVID-19 pandemic deserves careful consideration."],"journal":"Int J Environ Res Public Health","authors":["Mirabelli, Maria","Chiefari, Eusebio","Puccio, Luigi","Foti, Daniela Patrizia","Brunetti, Antonio"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32456064","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3390/ijerph17103664","keywords":["covid-19","dpp4 inhibitors","glp1 receptor agonists","sglt2 inhibitors","diabetes"],"topics":["Treatment"],"weight":1,"_version_":1667967698912411648,"score":94.69251},{"pmid":32383989,"title":"The Silver Lining to COVID-19: Avoiding Diabetic Ketoacidosis Admissions with Telehealth.","text":["The Silver Lining to COVID-19: Avoiding Diabetic Ketoacidosis Admissions with Telehealth.","Background: The Stay at Home order in Colorado and The Stay Safe at Home order in California during COVID-19 pandemic have forced a majority of the endocrinologists/diabetologists to adapt to providing diabetes care remotely through telehealth. This may provide increased access to diabetes health care in certain settings. However, health care disparities continue to challenge availability of diabetes technologies for underprivileged communities. We report our experience with two patients providing diabetes care effectively and preventing hospital admissions by using telehealth. Methods: Two adult patients with type 1 diabetes (T1D): one new onset and the other one with established T1D are presented where telehealth facilitated by Clarity Software and the \"Share\" feature with the use of Dexcom G6 continuous glucose monitoring (CGM) for management of diabetic ketosis and hyperglycemia. Results: Both patients were managed effectively virtually despite higher risk of diabetic ketoacidosis (DKA). Shared glucose data through CGM facilitated frequent insulin dose adjustments, increased fluid and carbohydrate intake, and prevented hospital admissions in both cases. In the case of new onset patient with T1D, most of the education was done remotely by certified diabetes care and education specialists. Conclusion: Acute diabetes complication like DKA increases morbidity and mortality in addition to adding cost to the health care system. The current pandemic of COVID-19 has allowed newer ways (with the help of newer technologies) to manage high-risk patients with T1D and DKA through telehealth and may result in lasting benefits to people with T1D.","Diabetes Technol Ther","Peters, Anne L","Garg, Satish","32383989"],"abstract":["Background: The Stay at Home order in Colorado and The Stay Safe at Home order in California during COVID-19 pandemic have forced a majority of the endocrinologists/diabetologists to adapt to providing diabetes care remotely through telehealth. This may provide increased access to diabetes health care in certain settings. However, health care disparities continue to challenge availability of diabetes technologies for underprivileged communities. We report our experience with two patients providing diabetes care effectively and preventing hospital admissions by using telehealth. Methods: Two adult patients with type 1 diabetes (T1D): one new onset and the other one with established T1D are presented where telehealth facilitated by Clarity Software and the \"Share\" feature with the use of Dexcom G6 continuous glucose monitoring (CGM) for management of diabetic ketosis and hyperglycemia. Results: Both patients were managed effectively virtually despite higher risk of diabetic ketoacidosis (DKA). Shared glucose data through CGM facilitated frequent insulin dose adjustments, increased fluid and carbohydrate intake, and prevented hospital admissions in both cases. In the case of new onset patient with T1D, most of the education was done remotely by certified diabetes care and education specialists. Conclusion: Acute diabetes complication like DKA increases morbidity and mortality in addition to adding cost to the health care system. The current pandemic of COVID-19 has allowed newer ways (with the help of newer technologies) to manage high-risk patients with T1D and DKA through telehealth and may result in lasting benefits to people with T1D."],"journal":"Diabetes Technol Ther","authors":["Peters, Anne L","Garg, Satish"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32383989","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1089/dia.2020.0187","keywords":["cgm","covid-19","diabetic ketoacidosis","health care disparities","new onset type 1 diabetes","telehealth"],"locations":["Colorado","California"],"countries":["United States"],"countries_codes":["USA|United States"],"e_drugs":["Silver","Carbohydrates","Glucose"],"topics":["Prevention"],"weight":1,"_version_":1666419683378593792,"score":54.65207},{"pmid":32473903,"title":"Does poor glucose control increase the severity and mortality in patients with diabetes and COVID-19?","text":["Does poor glucose control increase the severity and mortality in patients with diabetes and COVID-19?","BACKGROUND AND AIM: Diabetes in often associated with an increased severity and mortality in patients with COVID-19. We aimed to find out whether the severity and mortality in patients with diabetes with COVID-19 has any correlation to the level of glycemic control. METHODS: A Boolean search was made in PubMed database using the specific keywords related to our objectives up till May 14, 2020 and full text of article retrieved with the supplements published in English language. RESULTS: Two studies available so far have studied the outcomes of severity and mortality in patients with diabetes stratified on glycemic control. Both the studies have unequivocally found that patients with poorly-controlled hyperglycemia (blood glucose >180 mg/dl) have significantly higher level of poor prognostic markers biochemically, compared to the well-controlled arms (blood glucose <180 mg/dl). Moreover, significant increase in severity and mortality was observed in cohorts with poorly-controlled blood glucose due to any cause (diabetes or stress hyperglycemia), compared to the well-controlled cohorts with COVID-19, even after the adjustment of multiple confounders. CONCLUSIONS: Poorly-controlled hyperglycemia increases the severity and mortality in patients with COVID-19. All treating physician must strive for a good glycemic control (blood glucose <180 mg/dl) in patients with or without diabetes.","Diabetes Metab Syndr","Singh, Awadhesh Kumar","Singh, Ritu","32473903"],"abstract":["BACKGROUND AND AIM: Diabetes in often associated with an increased severity and mortality in patients with COVID-19. We aimed to find out whether the severity and mortality in patients with diabetes with COVID-19 has any correlation to the level of glycemic control. METHODS: A Boolean search was made in PubMed database using the specific keywords related to our objectives up till May 14, 2020 and full text of article retrieved with the supplements published in English language. RESULTS: Two studies available so far have studied the outcomes of severity and mortality in patients with diabetes stratified on glycemic control. Both the studies have unequivocally found that patients with poorly-controlled hyperglycemia (blood glucose >180 mg/dl) have significantly higher level of poor prognostic markers biochemically, compared to the well-controlled arms (blood glucose <180 mg/dl). Moreover, significant increase in severity and mortality was observed in cohorts with poorly-controlled blood glucose due to any cause (diabetes or stress hyperglycemia), compared to the well-controlled cohorts with COVID-19, even after the adjustment of multiple confounders. CONCLUSIONS: Poorly-controlled hyperglycemia increases the severity and mortality in patients with COVID-19. All treating physician must strive for a good glycemic control (blood glucose <180 mg/dl) in patients with or without diabetes."],"journal":"Diabetes Metab Syndr","authors":["Singh, Awadhesh Kumar","Singh, Ritu"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32473903","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.dsx.2020.05.037","keywords":["covid-19","diabetes","glycemic control","mortality","sars-cov-2","severity"],"locations":["Boolean"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668341932744507393,"score":46.752995},{"pmid":32412693,"title":"Personalized risk-benefit ratio adaptation of Breast Cancer care at the epicentre of Covid-19 outbreak.","text":["Personalized risk-benefit ratio adaptation of Breast Cancer care at the epicentre of Covid-19 outbreak.","Northern Italy has been one of the European regions reporting the highest number of Covid-19 cases and deaths. The pandemic spread has challenged the National Health System (NHS), requiring re-allocation of most of the available healthcare resources to treat Covid-19 positive patients, generating a competition with other healthcare needs, including cancer. Cancer patients are at higher risk of developing critical illness after Covid-19 infection. Thus, mitigation strategies should be adopted to reduce the likelihood of infection in all cancer patients. At the same time, suboptimal care and treatments may result in worse cancer-related outcome. In this paper, we attempt to estimate the individual risk-benefit balance to define personalized strategies for optimal breast cancer management, avoiding as much as possible a general untailored approach. We discuss and report the strategies our Breast Unit adopted from the beginning of the Covid-19 outbreak to ensure the continuum of the best possible cancer care for our patients while mitigating the risk of infection, despite limited healthcare resources.","Oncologist","Viale, Giulia","Licata, Luca","Sica, Lorenzo","Zambelli, Stefania","Zucchinelli, Patrizia","Rognone, Alessia","Aldrighetti, Daniela","Di Micco, Rosa","Zuber, Veronica","Pasetti, Marcella","Di Muzio, Nadia","Rodighiero, Maria Grazia","Panizza, Pietro","Sassi, Isabella","Petrella, Giovanna","Cascinu, Stefano","Gentilini, Oreste Davide","Bianchini, Giampaolo","32412693"],"abstract":["Northern Italy has been one of the European regions reporting the highest number of Covid-19 cases and deaths. The pandemic spread has challenged the National Health System (NHS), requiring re-allocation of most of the available healthcare resources to treat Covid-19 positive patients, generating a competition with other healthcare needs, including cancer. Cancer patients are at higher risk of developing critical illness after Covid-19 infection. Thus, mitigation strategies should be adopted to reduce the likelihood of infection in all cancer patients. At the same time, suboptimal care and treatments may result in worse cancer-related outcome. In this paper, we attempt to estimate the individual risk-benefit balance to define personalized strategies for optimal breast cancer management, avoiding as much as possible a general untailored approach. We discuss and report the strategies our Breast Unit adopted from the beginning of the Covid-19 outbreak to ensure the continuum of the best possible cancer care for our patients while mitigating the risk of infection, despite limited healthcare resources."],"journal":"Oncologist","authors":["Viale, Giulia","Licata, Luca","Sica, Lorenzo","Zambelli, Stefania","Zucchinelli, Patrizia","Rognone, Alessia","Aldrighetti, Daniela","Di Micco, Rosa","Zuber, Veronica","Pasetti, Marcella","Di Muzio, Nadia","Rodighiero, Maria Grazia","Panizza, Pietro","Sassi, Isabella","Petrella, Giovanna","Cascinu, Stefano","Gentilini, Oreste Davide","Bianchini, Giampaolo"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32412693","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1634/theoncologist.2020-0316","keywords":["covid-19","sars-cov-2","breast cancer","treatment"],"topics":["Prevention"],"weight":1,"_version_":1666897318920585216,"score":44.128506}]}